Graph not available
Graph not available

Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Medicamen Biotech Ltd Performance

Today's Low
493.00
arrowIcon
Today's High
534.95
52 Wk Low
355.45
arrowIcon
52 Wk High
845.00


Open

521

Traded Value (Cr)

1.06 Cr

Prev. Close

519.5

VWAP

511.49

Volume

8,818

Face Value

10

Medicamen Biotech Ltd Fundamentals

Market Cap
₹ 632 Cr
P/E Ratio (TTM)
54.48
P/B Ratio
3.17
Debt to Equity
0.15
ROE
6.68 %
EPS (TTM)
9.18
Dividend Yield
0.20%
Book Value
158.01

Click here to know more about Fundamentals

Medicamen Biotech Ltd Financials

Medicamen Biotech Ltd Financials

Medicamen Biotech Ltd Shareholding Pattern

Held By Mar 2024 Dec 2023 Sep 2023 Jun 2023
Promoters 43.21 % 43.21 % 43.21 % 43.21 %
Retail 31.95 % 31.90 % 31.80 % 31.43 %
Others 24.73 % 24.68 % 24.78 % 25.21 %
FII 0.11 % 0.21 % 0.21 % 0.16 %
Mutual Funds 0.00 % 0.00 % 0.00 % 0.00 %

Promoters

43.21%

Retail

31.95%

Others

24.73%

FII

0.11%

Mutual Funds

0.00%

Promoters

43.21%

Retail

31.90%

Others

24.68%

FII

0.21%

Mutual Funds

0.00%

Promoters

43.21%

Retail

31.80%

Others

24.78%

FII

0.21%

Mutual Funds

0.00%

Promoters

43.21%

Retail

31.43%

Others

25.21%

FII

0.16%

Mutual Funds

0.00%

Resistance and Support

₹527.53

PIVOT

resistance-arrow
Resistance
First Resistance₹543.867
Second Resistance₹570.483
Third Resistance₹586.817
support-arrow
Support
First Resistance₹500.917
Second Resistance₹484.583
Third Resistance₹457.967
RSI64.807
MACD68.678
ADX47.955
CCI40.733

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day8,8184,73453.69
Week26,01810,69758.21
1 Month64,74924,86156.68
6 Months19,71512,62164.02

About Medicamen Biotech Ltd

Medicamen Biotech Ltd is a widely held, Globally Recognized public limited company engaged in manufacturing and marketing of pharmaceutical formulations in overseas and domestic markets. The company is engaged in manufacture and distribution of medicines. They manufacturer and supply the range of products such as tablets, capsules, liquid syrup and dry syrup (beta lactum and non beta lactum) and ointment. The company has two manufacturing facilities namely, Bhiwadi (Rajasthan) and Haridwar (Uttarakhand). The Bhiwadi unit has ultra modern production facilities incorporating latest state of the art technology with a combination of technically qualified personnel and hardworking workforce. In Haridwar unit, the company manufactures Non-Betalactum preparations including tablets, capsules, oral liquids and ointments & creams. The company is committed to produce and provide quality medicines at competitive price for domestic as well as international markets thereby being socially responsible and rendering services to the medical Fraternity. Medicamen Biotech Ltd was incorporated on December 1993 and started their operation as distributor and manufacturer of medicines on loan license basis. The distribution activities were spread manifold over a wide market extending beyond the domestic market and started exporting to CIS countries. The vast distribution network with demand for low cost medicines prompted the company to go for own manufacturing facilities. Thus, in the year 1994, a land of 210,000 square feet in the Industrial town of Bhiwadi in the state of Rajasthan was procured. In the year 1995, the company was enlisted in Bombay Stock Exchange. In the year 2005, the company installed the second unit in the tax free zone at Haridwar in Uttarakhand, keeping the space with the ever increase in demand and fulfilling the commitment. During the year 2006-07, the company added Analgesic and Anti bacterial, Anti filarial and Anti TB products in its range and done two mega projects of Govt. of India related to Anti filarial and Anti TB drugs. They also supplied Anti bacterial products like Cotrimoxazole and Anti Analgesics like Paracetamol in bulk to their foreign partners. During the year, the company increased the production capacity of Tablets by 600 lakh Nos to 7800 lakh Nos. The second unit in Haridwar became fully operational from April 2007 with ultra modern manufacturing facilities comprises of Non Betalactum Tablets, Capsules, oral liquids & ointments with the production capacity of 4100 lakh Nos, 600 lakh Nos, 6 lakh Litre and 0.30 lakh kg respectively. The company upgraded the Bhiwadi unit with a consolidated cost of more than Rs 2.5 crore under the latest WHO guidelines on CGMP.' The Company launched the marketing division in Jan'09, with 16 products in Delhi & Uttrakhand regions. On September 16, 2015, M/s. Shivalik Rasayan Limited (Acquirer) got into two Share Purchase Agreements(SPAs) with Promoters of the Company - SPA 1 with Mr. Bal Kishan Gupta, Mr. Ashutosh Gupta, Ms. Ritu Gupta, Ms. Suchita Gupta and SPA 2 with Mr. Abhishek Bansal, Ms. Manju Bansal, Mr. Sanjay Bansal and Ms. Ayushi Bansal for the acquisition of 44,12,095 fully paid-up Equity Shares of Rs.10/- each representing 44.15% of the paid up equity share capital of the Company through which the Acquirer made a Takeover Open Offer Transaction to acquire 26% of the Paid up Capital of the Company, which was completed in December, 2015 and the Acquirer became New Promoter of the Company. The Company acquired 100% stake of OPAL Pharmaceuticals Pty Ltd from its existing shareholder aggregating upto (AUD) $4,20,000 in 2019-20. OPAL, a wholly owned subsidiary of the Company, merged with the Company effective September 17, 2019. The Company has launched 12 Oncology products in domestic market effective from January, 2022.

Managing Director

Founded

1993

NSE Symbol

MEDICAMEQ

Medicamen Biotech Ltd Management

NameDesignation
Sanjay BansalNon Executive Director
Rahul BishnoiChairman (Non-Executive)
Ashwani Kumar SharmaNon Executive Director
Harish PandeIndependent Director
S K SinghNon Executive Director
Arun KumarIndependent Director
Parul ChoudharyCompany Sec. & Compli. Officer
Sumita DwivediIndependent Director
Vimal Kumar Shrawat.Non Executive Director
Sangeeta BishnoiIndependent Director
Ravi Kumar BansalIndependent Director

Medicamen Biotech Ltd News

Medicamen Biotech consolidated net profit declines 46.01% in the December 2023 quarter
Sales rise 30.69% to Rs 46.50 crore
Medicamen Biotech to conduct board meeting
On 12 February 2024
Medicamen Biotech consolidated net profit declines 58.06% in the September 2023 quarter
Sales rise 29.85% to Rs 43.54 crore
Medicamen Biotech to convene board meeting
On 10 November 2023
Medicamen Biotech to conduct AGM
On 27 September 2023
Medicamen Biotech consolidated net profit rises 16.43% in the June 2023 quarter
Sales rise 26.75% to Rs 41.94 crore
Medicamen Biotech to discuss results
On 8 August 2023
Board of Medicamen Biotech recommends final dividend
Of Rs 1 per share
Medicamen Biotech consolidated net profit rises 41.45% in the March 2023 quarter
Sales rise 69.98% to Rs 38.67 crore
Medicamen Biotech standalone net profit rises 47.27% in the March 2023 quarter
Sales rise 63.30% to Rs 37.15 crore

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
SUNPHARMA₹ 3,58,616 Cr
₹ 1,494.65
(-1.78 %)
86.97
CIPLA₹ 1,09,708 Cr
₹ 1,358.80
(-1.87 %)
33.36
DIVISLAB₹ 1,00,611 Cr
₹ 3,789.95
(-3.50 %)
73.75
DRREDDY₹ 98,044 Cr
₹ 5,877.35
(-2.96 %)
22.59
ZYDUSLIFE₹ 97,423 Cr
₹ 968.20
(-3.72 %)
36.23

Medicamen Biotech Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Medicamen Biotech Ltd shares in BlinkX

The share price of any stock is volatile and changes during the day due to a variety of variables. Medicamen Biotech Ltd's share price is ₹499.85 as of May 9, 2024

Medicamen Biotech Ltd's P/E ratio is 54.48 times as of May 9, 2024.

Medicamen Biotech Ltd's most recent financial reports indicate a price-to-book ratio of 3.17, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Medicamen Biotech Ltd's market is 633 Cr as on May 9, 2024.

The current financial records of Medicamen Biotech Ltd show a 6.68% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

The 52-week high/low price of a Medicamen Biotech Ltd stock is the highest and lowest price at which it has traded over that period (about one year) and is used as a technical indicator. Medicamen Biotech Ltd's 52-week high and low as of May 9, 2024 are ₹534.95 and ₹493 respectively.

As of the Mar 2024 quarter, the promoter shareholding in Medicamen Biotech Ltd stands at 43.21%. During the same period, Institutional Investors have shown a slight decrease in their holdings, dropping from 0.21% to 0.11%.